Nanobiotix Shares Fall by 2.5%, Down Nearly 19% Over the Month
The French biotech company continues its downward trend, even as the Paris stock market shows positive movement. The stock is still adjusting after reaching a record high in mid-May, in a market context characterized by a strong dollar comeback and easing Brent crude prices. Selling pressure remains strong despite an exceptional annual performance.
The Stock Falls Below its Short-Term Moving Averages and Ranks at the Bottom of the Index
Nanobiotix is down 2.25% at €29.50 by mid-morning, while the SBF 120 index is up 0.20%. The stock is among the largest declines in the broad index, moving against the grain of a Parisian market buoyed by a rebound in semiconductors (Soitec, STMicroelectronics) and easing geopolitical tensions in the Middle East. The decline extends a short-term negative trend: the stock has lost nearly 19% over the month and 3.85% over the week, after reaching a historic peak in mid-May.
The price is below its 20-day moving average (MM20) of €30.87 (a gap of -4.44%) and its 50-day moving average (MM50) of €32.55 (a gap of -9.37%), indicating the exhaustion of the short-term movement. The 200-day moving average (MM200) remains well below the current price at €23.08, a gap of more than 27%, reflecting the magnitude of the annual rally (+663%). The RSI at 44 remains neutral and does not yet indicate a seller exhaustion zone, while the support level at €28.28 is approaching, about 4% below the current price.
Strengthening of Cash Reserves and Clinical Advances Remain Fundamental
Beyond the session, the stock maintains a robust fundamental base. In early June, the biotech announced a cash reserve reinforcement through a capital increase of €86.1 million, bringing net liquidity to €42.1 million as of March 31, 2026. Preliminary Phase 2 data on JNJ-1900 (NBTXR3) in inoperable lung cancer were also presented, with a response observed in six out of seven treated patients.
During the first quarter of 2026 publication (June 2), the company highlighted opportunities in advancing clinical studies on this molecule and strengthening the Nanoprimer platform. The integration into the Euronext Tech Leaders segment, finalized in early June, provides increased visibility among international investors, though it has not been sufficient to halt the consolidation. The support at €28.28 will be the next technical reference point if selling pressure intensifies.
